198 related articles for article (PubMed ID: 15673763)
1. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.
Lin G; Credito K; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2005 Feb; 49(2):770-2. PubMed ID: 15673763
[TBL] [Abstract][Full Text] [Related]
2. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
[TBL] [Abstract][Full Text] [Related]
3. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.
Lopez S; Hackbarth C; Romanò G; Trias J; Jabes D; Goldstein BP
J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii21-4. PubMed ID: 15750033
[TBL] [Abstract][Full Text] [Related]
4. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Hoellman DB; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
[TBL] [Abstract][Full Text] [Related]
5. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
Mushtaq S; Warner M; Johnson AP; Livermore DM
J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
[TBL] [Abstract][Full Text] [Related]
6. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Streit JM; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Jones RN; Fritsche TR; Sader HS; Goldstein BP
J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
[TBL] [Abstract][Full Text] [Related]
11. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Biedenbach DJ; Ross JE; Fritsche TR; Sader HS; Jones RN
J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
13. Antipneumococcal activity of dalbavancin compared to other agents.
Lin G; Smith K; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2005 Dec; 49(12):5182-4. PubMed ID: 16304200
[TBL] [Abstract][Full Text] [Related]
14. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
15. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Credito K; Lin G; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
[TBL] [Abstract][Full Text] [Related]
16. Adverse effect of staphylococci slime on in vitro activity of glycopeptides.
Mathur T; Singhal S; Khan S; Upadhyay D; Fatma T; Rattan A
Jpn J Infect Dis; 2005 Dec; 58(6):353-7. PubMed ID: 16377866
[TBL] [Abstract][Full Text] [Related]
17. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
18. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Streit JM; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity and resistance development profiling of dalbavancin.
Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
